{
    "Trade/Device Name(s)": [
        "LZI Fentanyl II Enzyme Immunoassay"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K201938",
    "Predicate Device Reference 510(k) Number(s)": [
        "K181159"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "August 7, 2020",
    "Summary Letter Received Date": "July 13, 2020",
    "Submission Date": "July 2, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Norfentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU480 automated clinical analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Fentanyl II Enzyme Immunoassay for qualitative determination of norfentanyl in urine on automated clinical chemistry analyzers.",
    "Indications for Use Summary": "Qualitative determination of norfentanyl in human urine at a cutoff of 5 ng/mL for prescription use with automated clinical chemistry analyzers; provides a preliminary analytical result, with confirmation required by a more specific alternative chemical method.",
    "fda_folder": "Toxicology"
}